CLL Follow-up Post-test and Survey

Which best describes your practice setting? *

Academic

Community

Other

How many patients with CLL do you provide care for in a typical month? *

Patient Case 1: Patient With CLL Previously Treated With BTK Inhibitor and Venetoclax-Based Therapy

62-yr-old male with CLL was treated with ibrutinib with excellent disease control but developed progressive disease after 4 yr
- Found to have BTK C481S mutation on further testing
Subsequently received treatment with venetoclax + rituximab but developed progressive disease at conclusion of his planned 24 mo of treatment

Case 1: Which therapeutic approach would you consider optimal for this patient? *

Retreat with venetoclax + anti-CD20 monoclonal antibody

Bendamustine + rituximab

Ibrutinib + venetoclax

Acalabrutinib

Pirtobrutinib

Zanubrutinib

PI3K inhibitor‒based therapy (duvelisib or idelalisib)

Based on evidence from the phase III ELEVATE-RR trial, which of the following accurately describes the relative incidence of any-grade cardiovascular toxicities with acalabrutinib vs ibrutinib? *

Similar atrial fibrillation and hypertension rates

Lower atrial fibrillation and similar hypertension rates

Lower hypertension and similar atrial fibrillation rates

Lower atrial fibrillation and hypertension rates

Patient Case 2: Patient With Previously Untreated CLL

67-yr-old woman was diagnosed incidentally 3 yr ago after screening mammogram identified small LAD and biopsy consistent with CLL/SLL
Markers at diagnosis:
- FISH: 36% deletion of 17p
- IGHV unmutated
- TP53 mutation
Other medical problems: hypertension; otherwise very active and asymptomatic
Progresses over 3 yr with lymphocytosis (45,000-104,000 over past 6 mo), anemia (12.1 g/dL at baseline to 9.7 g/dL), and thrombocytopenia (165K at baseline to 87K); no other causes for lymphocytosis or anemia identified; spleen 17 cm CC on scans; all LNs ≤3 cm
Symptomatic with fatigue but continues to work full time and travels frequently

Case 2: Which of the following would you consider optimal for this patient? *

Chemoimmunotherapy (eg, FCR)

First-generation BTK inhibitor (ibrutinib)

Second-generation BTK inhibitor (acalabrutinib or zanubrutinib)

Venetoclax + obinutuzumab

Ibrutinib + venetoclax

After participation in this activity, did you make changes in your professional practice? *

Yes

I already practice these recommendations

No, there are too many barriers

Please select any of the following strategies that you have implemented in your practice setting: *

Select all that apply.

Apply latest NCCN guidelines

Better communicate treatment plans to patients and/or caregivers

Better communication with other members of the health care team

Change in diagnostic testing

Change in non-pharmaceutical therapy

Change in pharmaceutical therapy

Educate the health care team on new information

Improve shared decision making with patients and/or caregivers

Plan to enroll patients in clinical trials

Please select any of the following barriers that you have experienced in your practice setting: *

Select all that apply.

Administrative/leadership/health system barriers

As part of the health care team, we need additional education to improve performance of the team.

I need additional education to improve my performance.

Ineffective communication among health care team members

Insurance/financial issues

Patient adherence/compliance issues

Time/resource constraints

What do you consider when selecting frontline therapy for patients with CLL?

What do you consider when selecting second-line and beyond therapy for patients with CLL/SLL?

What do you see as key challenges in managing your patients with CLL?

What are the greatest barriers to treatment you have observed in your patients with CLL/SLL?

You are here